The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1375-1386, Marson, A.,et al, 2021
Review of the Utility of Prophylactic Anticonvulsant Use in Critically Ill Patients with Intracerebral Hemorrhage
Stroke 47:2666-2672, Gilmore, E.J.,et al, 2016
Evidence-Based Guideline: Management of an Unprovoked First Seizure in Adults
Neurol 84:1705-1713, Krumholz, A.,et al, 2015
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
Stroke 41:2108-2129, Morgenstern,L.B.,et al, 2010
The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009
A 24-Year-Old Woman with Intractable Seizures: Review of Surgery for Epilepsy
JAMA 300:2527-2538,2568, Schomer,D.I. &Black,P.M., 2008
The First Seizure and Its Management in Adults and Children
BMJ 332:339-342, Pohlmann-Eden,B.,et al, 2006
Practice Parameter: Treatment of the Child with a First Unprovoked Seizure
Neurol 60:166-175, Hirtz,D.,et al, 2003
Prognosis for Seizure Recurrence in Patients with Newly Diagnosed Neurocysticercosis
Neurol 59:1730-1734,1669, Carpio,A. &Hauser,W.A., 2002
A Randomized, Controlled Trial of Surgery for Temporal-Lobe Eiplepsy
NEJM 345:311-318,365, Wiebe,S.,et al, 2001
New Drugs:Which Should Be Included in the Formulary?, Epilepsy:All New Drugs Should Be Included
Arch Neurol 57:272-273,275, Pierre-Louis,S.J.C., 2000
Restrictions on the Availability of Antiepileptic Drugs
Arch Neurol 57:273-274,275, Bergen,D.C., 2000
Therapeutic Dilemma
Neurol 54:1404-1407, Romanelli,F.,et al, 2000
Anticonvulsant Prophylaxis and Timing of Seizures After Aneurysmal Subarachnoid Hemorrhage
Neurol 55:258-265, Rhoney,D.H. et al, 2000
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Which Unruptured Cerebral Aneurysms Should be Treated? A Cost-Utility Analysis
Neurol 52:1806-1815, Johnston,S.C.,et al, 1999
Do Nonconvulsive Seizures Damage the Brain? Yes
Arch Neurol 55:117-120, Young,G.C.&Jordan,K.G., 1998
Do Nonconvulsive Seizures Damage the Brain? No
Arch Neurol 55:119-120, Aminoff,M.J., 1998
Vagus Nerve Stimulation for Treatment of Seizures? Yes
Arch Neurol 55:231-232, 2341998., Ben-Menachem,E., 1998
Vagus Nerve Stimulation for Treatment of Seizures? Maybe
Arch Neurol 55:232-234, McLachlan,R.S., 1998
Do New Antiepileptic Drugs Justify Their Expense
Arch Neurol 55:1140-1142, Chadwick,D., 1998
Early Treatment of a Single Generalized Tonic-Clonic Seizure to Prevent Recurrence
Arch Neurol 53:1149-1152, Gilad,R.,et al, 1996
Do Anticonvulsants Alter the Natural Course of Epilepsy
BMJ 310:176-178, Reynolds,E.H.&Chadwick,D., 1995
A Continuing Controversy:Magnesium Sulfate in the Treatment of Eclamptic Seizures
Arch Neurol 47:1031-1032, Kaplan,P.W.,et al, 1990
No, Magnesium Sulfate Should Not Be Used in Treating Eclamptic Seizures
Arch Neurol 45:1361-1364, Kaplan,P.W.,et al, 1988
First Seizure Management-Reconsidered, Response I, II, & III, Controversies in Neurology
Fisher, R. S. , Dasheiff, R. , Arch Neurol 44:1189-1191, Fromm,G.H., 1987
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults with Cancer
Neurol 105:e214325, Balali,P.,et al, 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Vascular Malformations of the Central Nervous System
www.UptoDate.Com, March, Singer,R.J.,et al, 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
NEJM 390:1745-1755, 1815, Connolly,S.J.,et al, 2024
Antithrombotic Therapy in Patients with Cerebral Microbleeds or Cortical Siderosis, Is This Contraindicated?
Neurol 100:551-552, Schneck,M.J., &Biller,J., 2023
Does Capturing Debris During TAVR Prevent Strokes?
NEJM 387:1318-1319, Carroll, J.D. & Saver, J.L., 2022
Screening for Asymptomatic Carotid Artery Stenosis US Preventive Services Task Force Recommendation Statement
JAMA 325:476-481, US Preventative Services Task Force, 2021
Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants
JAMA Neurol 78:515-518, Seiffge, D.J.,et al, 2021
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
NEJM 384:2081-2091,2154, Whitlock, R.P.,et al, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Intravenous Thrombolysis for Suspected Ischemic Stroke with Seizure at Onset
Ann Neurol 86:770-779, Polymeris, A.A.,et al, 2019
Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Non-Specific Low Back Pain
Lancet 389:736-747, Maher, C.,et al, 2017
Arteriovenous Malformations of the Brain
NEJM 376:1859-1866, Solomon, R.A. & Connolly, E.S., 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017